Search

948 Result(s)
Sort by

DCRI-collaboration-empact-mi

DCRI-collaboration-empact-mi

Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
EMPERIAL-heart-failure-toplineresults

EMPERIAL-heart-failure-toplineresults

Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
Driving Innovation through Diversity & Inclusion

Driving Innovation through Diversity & Inclusion

Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Siva Thotapalli

Siva Thotapalli

My career challenge at Boehringer Ingelheim by Siva Thotapalli. Read it now!
Grow Your Skills

Grow Your Skills

Great things in business are never done by one person; they’re done by a team of people
Valerie Nock

Valerie Nock

My career challengeFunctional Areas at Boehringer Ingelheim
George Okafo

George Okafo

My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
What we do

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Vaccine prevent calf diarrhea

Vaccine prevent calf diarrhea

Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
cystic fibrosis phase II trial

cystic fibrosis phase II trial

The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
We are Global Top Employer 2024

We are Global Top Employer 2024

Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor